Lancet Rheumatol 2023;5:e263–73 doi 10.1016/S2665-9913(23)00089-9
Investigators from a phase 2 study concluded that further investigation with BMS-986142 (a novel BTK) in people with RA is not necessary.
Conaghan et al. assessed the safety and efficacy of BMS-986142, on RA patients who had an inadequate MTX response. An absence of clinical benefit in this study, together with other study results, suggests the need for additional research. This research should further investigate the extent of BTK inhibition, treatment duration, and adequacy of drug distribution to inflammation sites, to understand the potential utility of BTK inhibition as a therapeutic strategy for rheumatoid arthritis.